ImmuPharma shares jump on lupus study data

Specialist UK-based drug discovery and development company ImmuPharma (LSE:IMM) is trading 25% higher than earlier this week following the presentation of positive data from the Lupuzor/P140 pharmacokinetic (PK) study.

ImmuPharma was required to provide this data by the US Food and Drug Administration (FDA), as part of the new optimized international Phase III trial of Lupuzor in lupus patients.

The data successfully demonstrates that the PK study has met the key endpoints requested by the FDA. Importantly, and in-line with all human dosing to date, P140 was also safe and well-tolerated across all doses and in all subjects.